MAXILUS

A Phase 3b, Open-label Study Evaluating the Efficacy and Safety of Luspatercept (BMS-986346/ACE-536) Initiated at Maximum Approved Dose in LR-MDS With IPSS-R Very Low-, Low-, or Intermediate-risk Who Require RBC Transfusions (MAXILUS)

Arms / Cohorts

Experimental, Cohort 1:Erythropoiesis-stimulating Agents (ESA) Naïve

Status
Status not available
Treatments
Treatments not available
Criteria
Criteria not available

Accepting patients

Experimental, Cohort 2:Erythropoiesis-stimulating Agents (ESA) Relapsed or Refractory

Status
Status not available
Treatments
Treatments not available
Criteria
Criteria not available

Accepting patients

Patient Screener(888) 803-1766

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.